Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.

Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, Li LS, Patel M, Cao L, Moore Z, Rommel A, Boatman M, Lewis C, Euhus DM, Bornmann WG, Buchsbaum DJ, Spitz DR, Gao J, Boothman DA.

Mol Cancer Ther. 2013 Oct;12(10):2110-20. doi: 10.1158/1535-7163.MCT-12-0962. Epub 2013 Jul 24.

2.

Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.

Chakrabarti G, Silvers MA, Ilcheva M, Liu Y, Moore ZR, Luo X, Gao J, Anderson G, Liu L, Sarode V, Gerber DE, Burma S, DeBerardinis RJ, Gerson SL, Boothman DA.

Sci Rep. 2015 Nov 25;5:17066. doi: 10.1038/srep17066.

3.

An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.

Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, Patel M, Parkinson EI, Wang Y, Williams NS, Gao J, Hergenrother PJ, Boothman DA.

Cancer Res. 2012 Jun 15;72(12):3038-47. doi: 10.1158/0008-5472.CAN-11-3135. Epub 2012 Apr 24.

4.

Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.

Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA.

Cancer Cell. 2016 Dec 12;30(6):940-952. doi: 10.1016/j.ccell.2016.11.006.

5.

β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.

Park EJ, Min KJ, Lee TJ, Yoo YH, Kim YS, Kwon TK.

Cell Death Dis. 2014 May 15;5:e1230. doi: 10.1038/cddis.2014.202.

6.

An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.

Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, Minna JD, Bornmann WG, Gao J, Boothman DA.

Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11832-7. Epub 2007 Jul 3.

7.

Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.

Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, Xie XJ, Brekken RA, Barnett CC, Bornmann WG, Gao J, Boothman DA.

Clin Cancer Res. 2011 Jan 15;17(2):275-85. doi: 10.1158/1078-0432.CCR-10-1983. Epub 2011 Jan 11. Erratum in: Clin Cancer Res. 2011 Mar 1;17(5):1210-1.

8.

Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.

Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, Reinicke KE, Srougi MC, Moore Z, Dong Y, Vo P, Kabbani W, Yang CR, Wang X, Fattah F, Morales JC, Motea EA, Bornmann WG, Yordy JS, Boothman DA.

Antioxid Redox Signal. 2014 Jul 10;21(2):237-50. doi: 10.1089/ars.2013.5462. Epub 2014 Apr 3.

9.

The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.

Silvers MA, Deja S, Singh N, Egnatchik RA, Sudderth J, Luo X, Beg MS, Burgess SC, DeBerardinis RJ, Boothman DA, Merritt ME.

J Biol Chem. 2017 Nov 3;292(44):18203-18216. doi: 10.1074/jbc.M117.813923. Epub 2017 Sep 15.

10.

NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.

Li LS, Reddy S, Lin ZH, Liu S, Park H, Chun SG, Bornmann WG, Thibodeaux J, Yan J, Chakrabarti G, Xie XJ, Sumer BD, Boothman DA, Yordy JS.

Mol Cancer Ther. 2016 Jul;15(7):1757-67. doi: 10.1158/1535-7163.MCT-15-0765. Epub 2016 Apr 12.

11.

Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.

Dong Y, Bey EA, Li LS, Kabbani W, Yan J, Xie XJ, Hsieh JT, Gao J, Boothman DA.

Cancer Res. 2010 Oct 15;70(20):8088-96. doi: 10.1158/0008-5472.CAN-10-1418. Epub 2010 Oct 12.

12.

NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.

Moore Z, Chakrabarti G, Luo X, Ali A, Hu Z, Fattah FJ, Vemireddy R, DeBerardinis RJ, Brekken RA, Boothman DA.

Cell Death Dis. 2015 Jan 15;6:e1599. doi: 10.1038/cddis.2014.564.

13.

Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).

Lamberti MJ, Vittar NB, da Silva Fde C, Ferreira VF, Rivarola VA.

Phytomedicine. 2013 Aug 15;20(11):1007-12. doi: 10.1016/j.phymed.2013.04.018. Epub 2013 Jun 7.

PMID:
23746950
14.

β-Lapachone increases phase II antioxidant enzyme expression via NQO1-AMPK/PI3K-Nrf2/ARE signaling in rat primary astrocytes.

Park JS, Lee YY, Kim J, Seo H, Kim HS.

Free Radic Biol Med. 2016 Aug;97:168-178. doi: 10.1016/j.freeradbiomed.2016.05.024. Epub 2016 May 28.

PMID:
27242267
15.

Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.

Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, Hoppel CL, Misico RI, Arzac GM, Burton G, Bornmann WG, Sutton D, Gao J, Boothman DA.

Clin Cancer Res. 2005 Apr 15;11(8):3055-64.

16.

Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair.

Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA.

J Biol Chem. 2006 Nov 3;281(44):33684-96. Epub 2006 Aug 17.

17.

β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells.

Park MT, Song MJ, Lee H, Oh ET, Choi BH, Jeong SY, Choi EK, Park HJ.

PLoS One. 2011;6(10):e25976. doi: 10.1371/journal.pone.0025976. Epub 2011 Oct 6.

18.

Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.

Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie XJ, Leff R, Laheru D, Boothman DA.

J Surg Oncol. 2017 Jul;116(1):83-88. doi: 10.1002/jso.24624. Epub 2017 Mar 27.

19.

Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.

Bentle MS, Reinicke KE, Dong Y, Bey EA, Boothman DA.

Cancer Res. 2007 Jul 15;67(14):6936-45.

20.

Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.

Li JZ, Ke Y, Misra HP, Trush MA, Li YR, Zhu H, Jia Z.

Toxicol Appl Pharmacol. 2014 Dec 15;281(3):285-93. doi: 10.1016/j.taap.2014.10.012. Epub 2014 Oct 29.

PMID:
25448047

Supplemental Content

Support Center